Fundraising FoxIAG Capital Partners — 2023 Investments
4 investments dated 2023 · listed companies and verified rows first · show all
Elucid develops artificial intelligence technology that analyzes CT images to identify hidden features of cardiovascular risk and guide personalized treatment of coronary artery disease.
AI & Machine LearningBiotechHealthtechMedical DevicesBoston, US
Blake Richards(Executive Officer)inKelly Huang(Executive Officer, Director)inRobert Braun(Director)
BoardEvan Melrose(Director)Rajesh Panda(Director)Michael Lesh(Director)
Co-investorsAngel Physicians FundAphelion CapitalBlueStone Venture PartnersMedTex Ventures LLC
Jana Care offers a smartphone-enabled at-home blood testing system using its Aina device, paper test strips, and a mobile app to detect key biomarkers for chronic disease management.
Digital HealthHealthtechMedical DevicesWatertown, US
Sidhant Jena(Executive Officer, Director)Timothy Richards(Executive Officer)Richard Williams(Executive Officer)inAnh Hoang-Lindsay(Chief Executive Officer)Michal Depa(Executive Officer, Director)
BoardEhsan Jabbarzadeh(Director)
Co-investorsHealthXCapitalInnova Capital Partners, LLCPatamar CapitalAgent CapitalFirst Avenue VenturesThe A-Team
Lucid Scientific develops Resipher, a technology for live, continuous, and noninvasive monitoring of cellular oxygen consumption rate to study cell metabolism.
BiotechDeep TechHardwareAtlanta, US
Samuel Walker Inman(Executive Officer, Director)Ian W. Hunter(Executive Officer, Director)
BoardDr. Gustavo Mahler(Director)in
Co-investorsDynamk CapitalGRA Venture
Swaybox Studios is a film production studio that creates long-form storytelling using practical puppetry techniques for the big screen.
Media & EntertainmentNew Orleans, US
Chris ArmandThomas WoodruffinTheresa Andersson(Executive Officer, Director)Ben Yip(Director)Chris Wedge(Director)Arthur Mintz(Executive Officer, Director)
Co-investorsInnovation Catalyst
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.